Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib vs investigator’s choice NHA in mCRPC with HRR mutations
CTR20180162Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olaparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by AstraZeneca. Started May 2019; status: terminated.
02
Drugs
olaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20180162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180162.